On June 30, 2022, the U.S. Food and Drug Administration (FDA) issued a warning letter to the Kratom Exchange, addressing significant concerns regarding the marketing practices and safety of kratom products. The letter highlights the potential health risks associated with kratom, a substance known for its psychoactive effects and addictive properties. The FDA underscored that certain claims made by the company about kratom’s efficacy in diagnosing, treating, or preventing diseases are not supported by scientific evidence and violate the Federal Food, Drug, and Cosmetic Act. This warning serves as a critical reminder of the regulatory scrutiny surrounding kratom and the necessity for companies to adhere to established safety and marketing standards. The FDA’s action aims to protect public health and ensure that consumers are adequately informed about the risks associated with kratom use.
Menu
